best supportive care


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia.

best supportive care

Ideal patient care, e.g., health care that meets the patient's nutritional, philosophical, psychological, physical, medical, surgical, and social needs.
See also: care
References in periodicals archive ?
More number of patients could benefit with best supportive care rather than CT as very small number of female lung cancer patients can complete all the cycles of chemotherapy.
10) For unresectable advanced or recurrent gastric adenocarcinoma, treatment with systemic chemotherapy improves quality of live (QOL) with marginal survival benefits compared with the best supportive care.
published a meta-analysis [3] of randomised trials answering the question of utility in terms of improving survival with chemotherapy compared to best supportive care (a mean average survival benefit of 6 months).
Treatment options are limited to either systemic palliative chemotherapy with best supportive care (BSC), BSC alone, and occasionally palliative surgery or radiotherapy.
The remaining options are sorafenib (Nexavar), sunitinib (Sutent), or best supportive care, Dr.
R2 (macroscopic residual tumor) resection patients can undergo the same adjunctive treatment as R1 resection patients unless performance status is poor, in which case best supportive care is recommended.
Na Trial In Myelodysplastic SyndromE) is a pivotal Phase III, multicenter, randomized trial, comparing rigosertib plus best supportive care to best supportive care alone, in high-risk MDS patients with excess blasts (5% to 30% bone marrow blasts), who are refractory, intolerant to, or have relapsed after azacitidine or decitabine treatment.
Patients enrolled in the XCITE study were randomized 2:1 to receive Xilonix or placebo plus, in each case, best supportive care.
The FRESCO trial is designed to evaluate the efficacy of fruquintinib versus placebo, with all patients receiving best supportive care (BSC), with a primary endpoint of overall survival (OS).
This Phase III trial was conducted to compare single-agent cetuximab plus best supportive care in a total of 572 patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer who had previously been treated with 5-fluorouracil or another thymidylate synthase inhibitor, and who had failed irinotecan and oxaliplatin.
In a phase III trial that randomized 463 patients to panitumumab plus best supportive care (n = 231) or best supportive care alone (n = 232), the benefit of panitumumab was confined to patients with wild-type KRAS tumors.
Patients with high performance status require the best supportive care.